Bildkälla: Stockfoto

Xbrane Biopharma: Biogen deal terminated (BIIB801) - Redeye

Redeye leaves its initial take on Xbrane following this mornings news that Xbrane has regained the full rights to BIIB801 following Biogen's termination of the deal.

Redeye leaves its initial take on Xbrane following this mornings news that Xbrane has regained the full rights to BIIB801 following Biogen's termination of the deal.
Börsvärldens nyhetsbrev
ANNONSER